Idecabtagene Vicleucel Is Well Tolerated and Effective in Relapsed/Refractory Myeloma Patients with Prior Allogeneic Stem Cell Transplantation

Lukas John(University of Hohenheim), Stefan Schönland(Heidelberg University), Carsten Müller‐Tidow(Heidelberg University), Marc S. Raab(Unknown), Ute Hegenbart(Heidelberg University), Sandra Sauer(Heidelberg University), Michael Hundemer(Heidelberg University), Peter Dreger(Heidelberg University), Anita Schmitt(Heidelberg University), Michael Schmitt(German Cancer Research Center)

Transplantation and Cellular Therapy

June 20, 2023

10.1016/j.jtct.2023.06.010

Cited by 9

Related Papers

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

|Blood|2001|1.4k

New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes

|Journal of Clinical Oncology|2012|965

Systemic immunoglobulin light chain amyloidosis

|Nature Reviews Disease Primers|2018|550

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

|Blood|2018|492

Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases

|Blood|2003|457